AbbVie Reports Third-Quarter 2026 Financial Results
NORTH CHICAGO, Ill., Oct. 30, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2026.
"AbbVie continues to deliver outstanding results, reflecting solid execution across our diverse portfolio," said Robert A. Michael, chairman and chief executive officer, AbbVie. "We also enhanced our long-term growth potential by securing key regulatory approvals, generating differentiated clinical data and completing the acquisition of Apogee Therapeutics. Given our strong outlook and significant momentum, we are once again increasing AbbVie's full-year guidance and raising our quarterly dividend."
Third-Quarter Results
Note: "Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
Recent Events
Full-Year 2026 Outlook
AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.76 - $13.96 to $13.95 - $13.99, which includes an unfavorable impact of $0.69 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2026. The company's 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the third quarter of 2026, as both cannot be reliably forecasted.
AbbVie does not provide a reconciliation of forward-looking non-GAAP financial measures, including adjusted diluted earnings per share to the most directly comparable generally accepted accounting principles in the United States (GAAP) financial measures because AbbVie is unable to predict with reasonable certainty, without unreasonable effort, the amount and timing of changes in fair value of contingent consideration, intangible asset impairments, acquisition and integration costs, litigation matters, income tax items and other adjustments. These items are uncertain, depend on various factors and could have a material impact on AbbVie's GAAP results for the guidance period.
Company Declares Dividend Increase of 5.2 Percent
AbbVie is announcing today that its board of directors declared an increase in the company's quarterly cash dividend from $1.73 per share to $1.82 per share beginning with the dividend payable on February 16, 2027 to shareholders of record as of January 15, 2027. This reflects an increase of approximately 5.2 percent, continuing AbbVie's strong commitment to returning cash to shareholders through a growing dividend. Since the company's inception in 2013, AbbVie has increased its quarterly dividend by 355 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Conference Call
AbbVie will host an investor conference call today at 8:00 a.m. Central Time to discuss our third-quarter performance. The call will be webcast through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the call will be available after 11:00 a.m. Central Time.
Non-GAAP Financial Results
Financial results for 2026 and 2025 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie's management believes non-GAAP financial measures provide useful information to investors regarding AbbVie's results of operations and assist management, analysts and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project," "estimate," "intend," "plan," "target," "may," "could" and "will," and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, drug pricing reform and government pricing programs, risks related to the use of artificial intelligence or other emerging technologies, and the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, tariffs and changes in U.S. and international trade policies, and other uncertainties and risks associated with global business operations. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made.
Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's most recently filed Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and in other documents AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Media:
Investors:
Cat Langel
Liz Shea
(708) 508-3524
(847) 935-2211
Todd Bosse
(847) 936-1182
Jeffrey Byrne
(847) 938-2923
AbbVie Inc.
Key Product Revenues
Quarter Ended September 30, 2026
(Unaudited)
% Change vs. 3Q25
Net Revenues (in millions)
Reported
Operational a
U.S.
Int'l.
Total
U.S.
Int'l.
Total
Int'l.
Total
NET REVENUES
$13,333
$4,071
$17,404
10.5 %
9.8 %
10.3 %
10.6 %
10.5 %
Immunology
7,315
1,850
9,165
16.8
14.1
16.3
15.6
16.6
Skyrizi
5,019
757
5,776
22.9
21.6
22.7
23.2
22.9
Rinvoq
1,924
782
2,706
23.4
25.1
23.9
26.4
24.3
Humira
372
311
683
(39.9)
(16.8)
(31.2)
(15.2)
(30.6)
Neuroscience
2,939
450
3,389
19.3
20.0
19.4
20.7
19.5
Vraylar
1,064
4
1,068
14.3
43.5
14.3
46.0
14.3
Botox Therapeutic
912
168
1,080
10.5
5.8
9.8
5.6
9.8
Ubrelvy
438
11
449
27.3
13.9
26.9
15.0
26.9
Qulipta
333
65
398
32.1
80.2
38.2
82.3
38.5
Vyalev
154
132
286
>100.0
55.6
>100.0
57.2
>100.0
Other Neuroscience
38
70
108
(36.0)
(15.3)
(23.9)
(14.6)
(23.5)
Oncology
973
723
1,696
(5.7)
11.1
0.8
11.4
0.9
Venclexta
385
418
803
13.0
8.7
10.7
8.6
10.7
Imbruvica b
340
182
522
(33.0)
(8.3)
(26.1)
(8.3)
(26.1)
Elahere
166
58
224
9.6
>100.0
31.0
>100.0
31.2
Epkinly c
43
65
108
>100.0
35.1
57.7
39.5
60.8
Other Oncology
39
—
39
>100.0
62.6
>100.0
62.6
>100.0
Aesthetics
723
453
1,176
(2.3)
0.1
(1.4)
(1.0)
(1.8)
Botox Cosmetic
388
281
669
2.4
8.6
4.9
6.5
4.1
Juvederm Collection
90
132
222
(6.3)
(15.4)
(11.9)
(15.3)
(11.8)
Other Aesthetics
245
40
285
(7.6)
5.5
(6.0)
6.5
(5.9)
Other Key Products
800
165
965
(3.5)
(7.1)
(4.1)
(4.9)
(3.7)
Mavyret
115
150
265
(21.2)
(9.7)
(15.1)
(7.4)
(13.9)
Creon
361
—
361
(2.2)
n/m
(2.2)
n/m
(2.2)
Linzess
324
15
339
3.2
31.1
4.2
31.8
4.2
a
"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
b
Reflects profit sharing for Imbruvica international revenues.
c
Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.
n/m = not meaningful
AbbVie Inc.
Key Product Revenues
Nine Months Ended September 30, 2026
(Unaudited)
% Change vs. 9M25
Net Revenues (in millions)
Reported
Operational a
U.S.
Int'l.
Total
U.S.
Int'l.
Total
Int'l.
Total
NET REVENUES
$37,163
$12,233
$49,396
9.9 %
14.0 %
10.9 %
10.7 %
10.1 %
Immunology
19,809
5,432
25,241
14.9
19.7
15.9
16.5
15.2
Skyrizi
13,561
2,203
15,764
25.0
28.9
25.6
24.9
25.1
Rinvoq
5,094
2,256
7,350
20.4
32.8
23.9
29.2
22.9
Humira
1,154
973
2,127
(46.7)
(13.8)
(35.4)
(15.2)
(35.9)
Neuroscience
8,169
1,323
9,492
20.7
27.6
21.6
22.7
20.9
Vraylar
3,034
10
3,044
17.0
44.9
17.1
42.8
17.1
Botox Therapeutic
2,618
513
3,131
12.7
12.6
12.7
8.3
12.0
Ubrelvy
1,147
33
1,180
26.5
31.7
26.7
29.6
26.6
Qulipta
872
172
1,044
32.0
97.2
39.6
91.2
38.9
Vyalev
371
372
743
>100.0
70.9
>100.0
64.0
>100.0
Other Neuroscience
127
223
350
(38.0)
(8.7)
(22.0)
(12.9)
(24.3)
Oncology
2,791
2,186
4,977
(9.5)
14.6
(0.3)
11.5
(1.5)
Venclexta
1,095
1,249
2,344
12.4
12.8
12.6
7.9
10.0
Imbruvica b
1,009
601
1,610
(36.1)
(2.9)
(26.8)
(2.9)
(26.8)
Elahere
487
146
633
7.4
>100.0
24.5
>100.0
23.3
Epkinly c
104
190
294
64.7
49.9
54.9
50.5
55.3
Other Oncology
96
—
96
>100.0
>100.0
>100.0
>100.0
>100.0
Aesthetics
2,188
1,456
3,644
0.5
4.3
2.0
0.9
0.7
Botox Cosmetic
1,159
906
2,065
6.9
13.1
9.5
8.7
7.6
Juvederm Collection
278
421
699
0.3
(9.8)
(6.0)
(11.8)
(7.2)
Other Aesthetics
751
129
880
(8.1)
1.0
(6.9)
(1.2)
(7.2)
Other Key Products
2,377
518
2,895
3.3
(6.2)
1.5
(9.7)
0.8
Mavyret
431
480
911
(8.8)
(7.8)
(8.3)
(11.2)
(10.1)
Creon
1,067
—
1,067
(5.4)
n/m
(5.4)
n/m
(5.4)
Linzess
879
38
917
25.5
19.9
25.2
16.0
25.0
a
"Operational" comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.
b
Reflects profit sharing for Imbruvica international revenues.
c
Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.
n/m = not meaningful
AbbVie Inc.
Consolidated Statements of Earnings
(Unaudited)
(in millions, except per share data)
Third Quarter
Ended September 30
Nine Months
Ended September 30
2026
2025
2026
2025
Net revenues
$ 17,404
$ 15,776
$ 49,396
$ 44,542
Cost of products sold
4,285
5,304
12,794
13,652
Selling, general and administrative
4,087
3,569
11,297
10,115
Research and development
2,567
2,319
7,383
6,517
Acquired IPR&D and milestones
216
2,680
1,251
3,751
Other operating income
(18)
—
(18)
(24)
Total operating costs and expenses
11,137
13,872
32,707
34,011
Operating earnings
6,267
1,904
16,689
10,531
Interest expense, net
700
667
2,024
1,972
Other expense, net
738
523
4,519
4,630
Earnings before income tax expense
4,829
714
10,146
3,929
Income tax expense
609
526
1,613
1,511
Net earnings
4,220
188
8,533
2,418
Net earnings attributable to noncontrolling interest
2
2
7
8
Net earnings attributable to AbbVie Inc.
$ 4,218
$ 186
$ 8,526
$ 2,410
Diluted earnings per share attributable to AbbVie Inc.
$ 2.37
$ 0.10
$ 4.79
$ 1.34
Adjusted diluted earnings per share a
$ 3.82
$ 1.86
$ 10.12
$ 7.29
Weighted-average diluted shares outstanding
1,772
1,772
1,772
1,772
a Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.
AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
(Unaudited)
1. Specified items impacted results as follows:
Quarter Ended September 30, 2026
(in millions, except per share data)
Earnings
Diluted
Pre-tax
After-tax a
EPS
As reported (GAAP)
$ 4,829
$ 4,218
$ 2.37
Adjusted for specified items:
Intangible asset amortization
1,669
1,419
0.79
Acquisition and integration costs
408
391
0.22
Change in fair value of contingent consideration
829
809
0.46
Other
131
(42)
(0.02)
As adjusted (non-GAAP)
$ 7,866
$ 6,795
$ 3.82
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Acquisition and integration costs primarily reflect costs related to the Apogee Therapeutics, Inc. acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2026 included acquired IPR&D and milestone expense of
$216 million on a pre-tax and $205 million on an after-tax basis, representing an unfavorable impact of $0.11 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows:
Quarter Ended September 30, 2026
(in millions)
Cost of
products
sold
SG&A
R&D
Other
operating
income
Interest
expense,
net
Other
expense,
net
As reported (GAAP)
$ 4,285
$ 4,087
$ 2,567
$ (18)
$ 700
$ 738
Adjusted for specified items:
Intangible asset amortization
(1,669)
—
—
—
—
—
Acquisition and integration costs
(4)
(250)
(142)
—
(12)
—
Change in fair value of contingent consideration
—
—
—
—
—
(829)
Other
(11)
(149)
—
18
—
11
As adjusted (non-GAAP)
$ 2,601
$ 3,688
$ 2,425
$ —
$ 688
$ (80)
3. The adjusted tax rate for the third quarter of 2026 was 13.6 percent, as detailed below:
Quarter Ended September 30, 2026
(dollars in millions)
Pre-tax
earnings
Income taxes
Tax rate
As reported (GAAP)
$ 4,829
$ 609
12.6 %
Specified items
3,037
460
15.1 %
As adjusted (non-GAAP)
$ 7,866
$ 1,069
13.6 %
AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
(Unaudited)
1. Specified items impacted results as follows:
Quarter Ended September 30, 2025
(in millions, except per share data)
Earnings
Diluted
Pre-tax
After-tax a
EPS
As reported (GAAP)
$ 714
$ 186
$ 0.10
Adjusted for specified items:
Intangible asset amortization
1,871
1,576
0.89
Intangible asset impairment
847
701
0.39
Acquisition and integration costs
212
207
0.12
Change in fair value of contingent consideration
776
755
0.43
Other
(40)
(119)
(0.07)
As adjusted (non-GAAP)
$ 4,380
$ 3,306
$ 1.86
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Intangible asset impairment reflects impairment charges of $847 million related to the Resonic and Durysta intangible assets. Acquisition and integration costs
primarily reflect costs related to the Capstan acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended September 30, 2025 included acquired IPR&D and milestone expense of
$2.7 billion on a pre-tax and after-tax basis, representing an unfavorable impact of $1.50 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows:
Quarter Ended September 30, 2025
(in millions)
Cost of
products
sold
SG&A
R&D
Other
expense,
net
As reported (GAAP)
$ 5,304
$ 3,569
$ 2,319
$ 523
Adjusted for specified items:
Intangible asset amortization
(1,871)
—
—
—
Intangible asset impairment
(847)
—
—
—
Acquisition and integration costs
(5)
(144)
(63)
—
Change in fair value of contingent consideration
—
—
—
(776)
Other
(34)
(13)
—
87
As adjusted (non-GAAP)
$ 2,547
$ 3,412
$ 2,256
$ (166)
3. The adjusted tax rate for the third quarter of 2025 was 24.5 percent, as detailed below:
Quarter Ended September 30, 2025
(dollars in millions)
Pre-tax
earnings
Income taxes
Tax rate
As reported (GAAP)
$ 714
$ 526
73.7 %
Specified items
3,666
546
14.9 %
As adjusted (non-GAAP)
$ 4,380
$ 1,072
24.5 %
AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
(Unaudited)
1. Specified items impacted results as follows:
Nine Months Ended September 30, 2026
(in millions, except per share data)
Earnings
Diluted
Pre-tax
After-tax a
EPS
As reported (GAAP)
$ 10,146
$ 8,526
$ 4.79
Adjusted for specified items:
Intangible asset amortization
5,106
4,353
2.45
Acquisition and integration costs
431
410
0.23
Change in fair value of contingent consideration
4,734
4,613
2.60
Other
631
95
0.05
As adjusted (non-GAAP)
$ 21,048
$ 17,997
$ 10.12
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Acquisition and integration costs primarily reflect costs related to the Apogee Therapeutics, Inc. acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2026 included acquired IPR&D and milestones expense of
$1.3 billion on a pre-tax and $1.2 billion on an after-tax basis, representing an unfavorable impact of $0.69 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows:
Nine Months Ended September 30, 2026
(in millions)
Cost of
products
sold
SG&A
R&D
Other
operating
income
Interest
expense,
net
Other
expense,
net
As reported (GAAP)
$ 12,794
$ 11,297
$ 7,383
$ (18)
$ 2,024
$ 4,519
Adjusted for specified items:
Intangible asset amortization
(5,106)
—
—
—
—
—
Acquisition and integration costs
(7)
(257)
(155)
—
(12)
—
Change in fair value of contingent consideration
—
—
—
—
—
(4,734)
Other
(20)
(377)
(221)
18
—
(31)
As adjusted (non-GAAP)
$ 7,661
$ 10,663
$ 7,007
$ —
$ 2,012
$ (246)
3. The adjusted tax rate for the first nine months of 2026 was 14.5 percent, as detailed below:
Nine Months Ended September 30, 2026
(dollars in millions)
Pre-tax
earnings
Income taxes
Tax rate
As reported (GAAP)
$ 10,146
$ 1,613
15.9 %
Specified items
10,902
1,431
13.1 %
As adjusted (non-GAAP)
$ 21,048
$ 3,044
14.5 %
AbbVie Inc.
Reconciliation of GAAP Reported to Non-GAAP Adjusted Information
(Unaudited)
1. Specified items impacted results as follows:
Nine Months Ended September 30, 2025
(in millions, except per share data)
Earnings
Diluted
Pre-tax
After-tax a
EPS
As reported (GAAP)
$ 3,929
$ 2,410
$ 1.34
Adjusted for specified items:
Intangible asset amortization
5,593
4,721
2.67
Intangible asset impairment
847
701
0.39
Acquisition and integration costs
273
256
0.14
Change in fair value of contingent consideration
5,089
4,941
2.79
Other
52
(75)
(0.04)
As adjusted (non-GAAP)
$ 15,783
$ 12,954
$ 7.29
a Represents net earnings attributable to AbbVie Inc. Specified items reflect the impact of applicable statutory tax rates.
Intangible asset impairment reflects impairment charges of $847 million related to the Resonic and Durysta intangible assets. Acquisition and integration costs
primarily reflect costs related to the Capstan acquisition.
Reported GAAP earnings and adjusted non-GAAP earnings for the nine months ended September 30, 2025 included acquired IPR&D and milestones expense of
$3.8 billion on a pre-tax and $3.6 billion on an after-tax basis, representing an unfavorable impact of $2.05 to both diluted EPS and adjusted diluted EPS.
2. The impact of the specified items by line item was as follows:
Nine Months Ended September 30, 2025
(in millions)
Cost of
products
sold
SG&A
R&D
Other
operating
income
Other
expense,
net
As reported (GAAP)
$ 13,652
$ 10,115
$ 6,517
$ (24)
$ 4,630
Adjusted for specified items:
Intangible asset amortization
(5,593)
—
—
—
—
Intangible asset impairment
(847)
—
—
—
—
Acquisition and integration costs
(10)
(171)
(92)
—
—
Change in fair value of contingent consideration
—
—
—
—
(5,089)
Other
(126)
(13)
(3)
24
66
As adjusted (non-GAAP)
$ 7,076
$ 9,931
$ 6,422
$ —
$ (393)
3. The adjusted tax rate for the first nine months of 2025 was 17.9 percent, as detailed below:
Nine Months Ended September 30, 2025
(dollars in millions)
Pre-tax
earnings
Income taxes
Tax rate
As reported (GAAP)
$ 3,929
$ 1,511
38.5 %
Specified items
11,854
1,310
11.1 %
As adjusted (non-GAAP)
$ 15,783
$ 2,821
17.9 %
SOURCE AbbVie